• Twenty-four patients classified as having Raynaud's disease or Raynaud's phenomenon were given bilateral brachial artery injections of reserpine or saline in a double-blind fashion. In the six weeks following injection, there was no indication that reserpine produced clinical improvement or changed vasomotor reactivity in the treated patients. However, intra-arterial reserpine did produce systemic cardiovascular effects lasting up to six weeks. It is concluded that intra-arterial reserpine as used in this study is an ineffective treatment for Raynaud's disease or Raynaud's phenomenon and may have significant adverse effects.
(Arch Dermatol 1983;119:733-735)
Surwit RS, Gilgor RS, Duvic M, Allen LM, Neal JA. Intra-arterial Reserpine for Raynaud's Syndrome: Systemic Reactions Without Therapeutic Benefit. Arch Dermatol. 1983;119(9):733–735. doi:10.1001/archderm.1983.01650330025008
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: